Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Santiago Thibaud, Jerrel Catlett, Saoirse Bodnar, MD Babu Mia, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Sundar Jagannath, Shambavi Richard, Samir Parekh

Blood (2023) 142 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2023-190772

Published: 2023

Journal Articles

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Darren Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Joshua Richter, Cesar Rodriguez, Larysa J Sanchez, Santiago Thibaud, Hearn Jay Cho, Shambavi Richard

Blood (2023) 142 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2023-177749

Published: 2023

Journal Articles

Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study

Lucia Y Chen, Santiago Thibaud, Ajai Chari, Joshua Richter, Hearn Jay Cho, Larysa J Sanchez, Cesar Rodriguez, Adriana C Rossi, Shambavi Richard, Samir Parekh, Sundar Jagannath

Blood (2023) 142 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2023-190368

Published: 2023

Journal Articles

Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy

Darren Denjay Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Hearn Jay Cho, Joshua Richter, Larysa J Sanchez, Santiago Thibaud, Cesar Rodriguez, Shambavi Richard

Blood (2023) 142 (Supplement 1): 92.

https://doi.org/10.1182/blood-2023-188310

Published: 2023

Journal Articles

Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients

Santiago Thibaud, William Genthe, Saoirse Bodnar, Alessandro Lagana, Jane Houldsworth, Ajai Chari, Adriana C Rossi, Cesar Rodriguez, Larysa J Sanchez, Shambavi Richard, Joshua Richter, Kenan Onel, Sundar Jagannath, Tehilla Brander, Samir Parekh

Blood (2023) 142 (Supplement 1): 534.

https://doi.org/10.1182/blood-2023-190878

Published: 2023

Journal Articles

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

James R. Berenson, MD, Noemi Silagan, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, Eli Forouzan, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Ralph V. Boccia, MD, Honghao Hank Yang, Stephen Lim, MD, Robert Vescio, MD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-143005

Published: 2020

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

James R. Berenson, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, MBA, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Youram Nassir, MD, Ravindranath Patel, MD, Alberto Bessudo, MD, Daniel Greenwald, MD, Ralph V. Boccia, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2019) 134 (Supplement_1): 1903.

https://doi.org/10.1182/blood-2019-131370

Published: 2019

Journal Articles

Homozygous Antithrombin Deficient Type II (99Leu to Phe mutation): Description of a Successful Outcome during Pregnancy

C. Muñoz Novas, C. Pascual, J. Sanchez, A. Rodriguez, G. Pérez, M. Kwon, A. Gomez-Pineda, J. Corral, J. Diez-Martín

Blood (2008) 112 (11): 4104.

https://doi.org/10.1182/blood.V112.11.4104.4104

Published: 2008

Journal Articles

The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease

Irene E. Zohn, Ivana De Domenico, Andrew Pollock, Diane McVey Ward, Jessica F. Goodman, Xiayun Liang, Amaru J. Sanchez, Lee Niswander, Jerry Kaplan

Blood (2007) 109 (10): 4174–4180.

https://doi.org/10.1182/blood-2007-01-066068

Published: 2007

Journal Articles

Activation of the P38 MAPK Pathway Mediates Resistance to Ara-C y Bcr/Abl Positive Cells.

Victor J. Sanchez, MD, Clara I. Aceves, MD, Juan C. Gomez, MD, Felix Manso, MD, Juan R. Romero, MD, Junia V. Melo, MD, Ricardo Sanchez-Prieto, MD

Blood (2005) 106 (11): 1528.

https://doi.org/10.1182/blood.V106.11.1528.1528

Published: 2005

Journal Articles

Treatment of Diffuse Large B Cell Lymphoma with CHOP and Rituximab. Results of a Multicenter Study with 236 Patients.

Blood (2005) 106 (11): 4736.

https://doi.org/10.1182/blood.V106.11.4736.4736

Published: 2005

Journal Articles

Subcellular distribution and characterization of acetylcholinesterase activities from sheep platelets: relationships between temperature- dependence and environment

J Sanchez-Yague, JA Cabezas, M Llanillo

Blood (1990) 76 (4): 737–744.

https://doi.org/10.1182/blood.V76.4.737.737

Published: 1990

NARROW

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study

Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy

Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

Homozygous Antithrombin Deficient Type II (99Leu to Phe mutation): Description of a Successful Outcome during Pregnancy

The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease

Activation of the P38 MAPK Pathway Mediates Resistance to Ara-C y Bcr/Abl Positive Cells.

Treatment of Diffuse Large B Cell Lymphoma with CHOP and Rituximab. Results of a Multicenter Study with 236 Patients.

Subcellular distribution and characterization of acetylcholinesterase activities from sheep platelets: relationships between temperature- dependence and environment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only